Crisaborole and atopic dermatitis skin biomarkers: an intrapatient randomized trial

ABSTRACT: Crisaborole ointment, 2%, is a nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the treatment of mild-to-moderate atopic dermatitis (AD). The mechanism of action (MOA) of crisaborole and its effects on lesional measures of disease severity are not yet well-defined. This phase 2a, single-center, vehicle-controlled, intrapatient study was designed to further characterize the MOA of crisaborole through evaluation of clinical efficacy and changes in skin biomarkers in adults (N = 40) with mild-to-moderate AD.

ORGANISM(S): Homo sapiens

PROVIDER: GSE133477 | GEO | 2019/06/29

REPOSITORIES: GEO